Xefocam (Lornoxicam) is commonly used to help with short-term relief of acute mild to moderate pain and the symptomatic relief of pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis.

What Xefocam Treats: Main Uses and Benefits

Xefocam is relevant in clinical settings for addressing symptoms related to inflammatory processes. It provides symptomatic support across various therapeutic domains, including chronic inflammatory joint disorders like rheumatoid arthritis and ankylosing spondylitis, degenerative conditions like osteoarthritis, and acute episodes of low back pain. Additionally, it is used for managing acute discomfort following surgical or dental procedures, as well as severe painful menses (dysmenorrhea).

In these scenarios, the medication is applied in addressing symptom clusters that interfere with daily functioning. The primary benefit is providing supportive relief that helps ease the overall symptom burden, supports general well-being during symptomatic phases during difficult episodes.

“The primary benefit is providing supportive relief that helps ease the overall symptom burden.”

---

Quick Fact: Relief for Pain and Inflammation

Xefocam is commonly used to help manage symptoms related to physical discomfort and symptoms related to inflammatory processes. It is often applied during phases when symptoms become more noticeable, contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. HPRA Summary of Product Characteristics

Xefocam (lornoxicam) is a non-steroidal anti-inflammatory drug (NSAID) used for the short-term relief of mild to moderate acute pain and for the symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis.

---

Who Cannot Use Xefocam (Contraindications)

This medication is not suitable for everyone. Do not use Xefocam if you have:

• A known allergy or hypersensitivity to lornoxicam, or a history of hypersensitivity reactions (like asthma, rhinitis, or hives) to other NSAIDs, including aspirin.
• Active gastrointestinal bleeding, a current peptic ulcer, or a history of recurrent peptic ulcers, hemorrhage, or perforation.
• Severe kidney impairment or severe liver impairment.
• Severe heart failure.
• A bleeding disorder, or confirmed/suspected cerebrovascular bleeding.
• Thrombocytopenia (low platelet count).
• Are pregnant (especially in the last three months) or breastfeeding.
• Are under 18 years of age, as safety and efficacy have not been established.

---

Use with Caution (Specific Warnings)

Special care and monitoring are required for patients with a history of heart failure, high blood pressure, fluid retention, mild to moderate kidney or liver impairment, and gastrointestinal diseases like Crohn's disease or ulcerative colitis.

Interactions with other medicines and products

The official regulatory profile for Xefocam documents several distinct interaction patterns primarily related to pharmacokinetic and pharmacodynamic effects.

Formal Restrictions and Exposure Modifiers

Co-administration with other Non-steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is formally stated to be avoided due to a documented increase in the risk of adverse effects. Xefocam is a substrate for the CYP2C9 isoenzyme, and official prescribing information addresses this by requiring a dose reduction for individuals identified as CYP2C9 poor metabolizers. An exposure-modifying interaction exists with Cimetidine, which is documented to increase the plasma concentrations of Lornoxicam. Xefocam may also increase the plasma levels of Lithium and Digoxin, potentially increasing their adverse effects.

Pharmacodynamic Risk Reinforcement

Combining Xefocam with certain medicinal products results in a documented, heightened risk of specific complications. Co-use with Anticoagulants (such as Warfarin or Heparin), Oral Corticosteroids, Anti-platelet agents, and SSRIs may enhance effects that lead to an increased risk of bleeding or ulceration. Similarly, co-administration with Ciclosporin or Tacrolimus is associated with an increased risk of nephrotoxicity. The therapeutic effects of Diuretics, ACE Inhibitors, and ARBs may be officially reduced when co-administered with Xefocam. Food intake may decrease the rate of absorption of Lornoxicam.

Mechanism of Action: How Xefocam Works

---

Blocking the Synthesis of Prostaglandins

Xefocam (lornoxicam) acts as a non-selective competitive inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This primary action prevents the conversion of the substrate, arachidonic acid, into prostaglandins and other eicosanoid mediators, establishing the drug's mechanism of interaction.

---

Modulating Nociceptive and Inflammatory Signaling

By suppressing the production of pro-inflammatory prostaglandins (like PGE2), the mechanism alters nociceptive and inflammatory signaling cascades. The resulting systemic reduction in prostaglandins leads to decreased sensitization of peripheral nociceptors, diminished local vasodilation and vascular permeability, and modulation of the hypothalamic temperature set-point.

---

Influence on Constitutive Regulatory Pathways

The drug's non-selective mechanism also affects COX-1, the enzyme responsible for synthesizing constitutive prostaglandins that regulate gastric mucosal integrity and renal blood flow. Inhibition here alters physiological processes related to platelet aggregation and mucosal defense, which are mechanistic consequences of non-selective COX inhibition.

Xefocam is authorized for use via oral administration (tablets) and parenteral routes, specifically intravenous (IV) and intramuscular (IM) injection. The oral dosage is defined by the condition being addressed. For acute pain, the total daily dose ranges from 8 mg to 16 mg, while the initial dose for inflammatory conditions is typically 12 mg daily. In either case, the total oral dose is administered in two or three divided doses and must not exceed 16 mg per day. Oral tablets must be taken with a sufficient quantity of liquid. Taking the tablets before meals is necessary to avoid potential reduction in the medicine's effectiveness.

The injectable form, which involves reconstituting a powder with its solvent, is reserved for short-term use and must be administered immediately after preparation. Its use is limited to a maximum of two consecutive days. Dosing for injection begins with an 8 mg single dose, with a maximum of 24 mg permitted on the first day, followed by a 16 mg daily maximum on subsequent days. Specific modifications apply to certain populations: the maximum dose must be reduced to 12 mg daily for patients with mild-to-moderate renal or hepatic impairment. The use of Lornoxicam is not recommended in individuals under 18 years of age due to a lack of safety and efficacy data.

Research Evidence / Overview of Studies for Xefocam

Evidence for Acute Pain Relief

The evidence related to Xefocam in acute pain is based primarily on short-term, randomized controlled trials (RCTs). These studies were generally conducted during periods of increased symptom activity, such as immediately following surgical procedures, including dental or minor surgical procedures. Researchers primarily focused on outcomes related to physical discomfort, measuring changes in pain intensity over short, defined time intervals, often in comparison to a placebo or other active control treatments.

These trials explored how symptoms evolved in the observed adult populations, with findings describing patterns in the measures of changes in pain reporting and the time taken for initial changes in discomfort to be measured, typically over the first 24 hours after a single administration. The research so far indicates that the evidence is primarily focused on these single-dose or very short-term scenarios.

Evidence for Symptomatic Relief of Chronic Arthritis

The evidence related to Xefocam for exploring symptoms related to chronic inflammatory joint disorders, such as osteoarthritis (OA) and rheumatoid arthritis (RA), includes intermediate-term RCTs and systematic evaluations. These studies were applied in research contexts involving fluctuating symptoms and conditions marked by functional limitations.

Research examined outcomes reflecting daily functioning or activity level, including measures of joint stiffness, overall pain intensity, and standardized indices of functional capacity (for OA) or joint tenderness and swelling counts (for RA). Studies reported how symptoms evolved in the observed adult populations over the specified trial period, with the core evidence describing patterns over treatment durations generally lasting 4 weeks to 3 months.

Long-Term Research and Study Durations

The available clinical data mainly describes patient observations across short- and intermediate-term periods. For acute pain, observation periods are often confined to 24 hours. For chronic inflammatory conditions like OA and RA, the most extensive controlled evidence describes effects over 4 to 12 weeks. Some studies have explored longer periods, with evidence up to one year's duration for patients, which helps contextualize how patients reported their experience. However, the comprehensive long-term effects are not fully established, and there is limited information on the durability of symptomatic patterns over many years.

Evidence in Special Populations

Research has explored the administration of Xefocam in certain specific patient groups, most notably the elderly (over 65 years). Regulatory sources and some open studies indicate that the medicine was evaluated in this age group, with research exploring dosing patterns for older adults. Findings describe group patterns related to how older patients reported their experience during short-term use.

Conversely, Xefocam has not been studied adequately for use in children and adolescents under age 18, and evidence on the necessary outcomes related to safety and effectiveness in this specific population remains insufficient.

What is Still Under Research and Unclear

The evidence highlights areas where understanding symptom patterns could be expanded. The results apply only to the populations studied, meaning individual predictions are not possible. The data show patterns related to symptom change only in the short-to-intermediate term, particularly for chronic conditions, where the follow-up durations were limited to a few months. Research has not extensively documented the long-term impact on functional capacity or disease markers beyond the immediate symptomatic phase. Finally, evidence for certain groups and the management of all types of acute or chronic conditions remains limited and heterogeneous.

Key Studies & References

1. Analysis of the Effectiveness of Lornoxicam and Flurbiprofen on Management of Pain and Sequelae Following Third Molar Surgery: A Randomized, Controlled, Clinical Trial
2. Summary of Product Characteristics (SPC) - Xefo (Lornoxicam) - Health Products Regulatory Authority (HPRA)

How to Store and Dispose of Xefocam? (Lornoxicam)

Official regulatory documents define strict storage and disposal requirements to maintain the product's quality and ensure environmental safety.

Requirement	Official Instruction
Temperature	Store at or below 25 °C (room temperature).
Protection	Keep in the original package to protect from light and moisture.
Safety	Store all medication out of the sight and reach of children.
Handling	Do not use the product after the expiry date shown on the container.
Disposal	Do not dispose of unused or expired medicine via household waste or sewage systems (e.g., toilets/drains).
Environmental	Return all unused medicine to a pharmacist so it can be disposed of safely, which helps to protect the environment.